Concepedia

Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial

Anton Pozniak, Martin Markowitz, Anthony Mills, Hans‐Juergen Stellbrink, Antonio Antela, Peré Domingo, Pierre‐Marie Girard, Keith Henry, Thai Nguyen, David Piontkowsky,

The Lancet Infectious Diseases · 2014 · 99 citations · 27 references

DOIFull text

Open access

Concepts

References

27

Prediction of Creatinine Clearance from Serum Creatinine

Donald W. Cockcroft, Henry Gault · ˜The œNephron journals/Nephron journals · 2008 · 15.4K citations

, , +15

Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents

Annals of Internal Medicine · 1998 · 5.2K citations

, , +17

British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008

B G Gazzard · HIV Medicine · 2008 · 1.1K citations · Full text

, , +17

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

Paul E. Sax, Edwin DeJesus, Anthony Mills et al. · The Lancet · 2012 · 444 citations

, , +17

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

Edwin DeJesus, Jürgen K. Rockstroh, Keith Henry et al. · The Lancet · 2012 · 346 citations · Full text

, , +17